Nov 6, 2026 · 7 min
Airbnb rallies as Moderna revives, while Oracle faces cloud doubts
Airbnb Jumps, Moderna Gains, Oracle Sinks
The episode connects three distinct market moves to changing growth expectations, partnership risk, and the hazards of an unregulated peptide market.
- 1Airbnb’s stronger outlook, revenue growth, expanding supply, and buyback authorization reinforce its market momentum.
- 2Moderna returned to quarterly profitability as COVID vaccine sales rebounded and investors awaited cancer-vaccine data.
- 3Oracle’s reported cloud arrangement with Microsoft raises wider questions about neocloud costs, delays, and capital demands.
Don't miss
The episode’s sharpest turn comes when the market roundup gives way to the unregulated online market for peptides marketed for cognition and aging.
The brief
Airbnb leads the market roundup after strong revenue growth, an improved fourth-quarter outlook, expanding supply, new features, and a large buyback authorization strengthen its case.
Moderna’s rally rests on a return to quarterly profitability and stronger COVID vaccine sales, while investors look ahead to data from its skin-cancer treatment pipeline.
Oracle falls after reports that Microsoft is winding down a cloud-computing arrangement, exposing broader concerns about neocloud economics, delays, and expensive capital.
The closing technology segment shifts from listed companies to an unregulated gray market, where unapproved peptides are sold online for cognitive enhancement and aging concerns.
Taken together, the episode contrasts visible corporate catalysts with harder-to-measure risks—from cloud partnerships and capital intensity to products circulating beyond regulatory oversight.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.